dobutamine (dobutrex) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the ß-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$5.0678 - $12.5411
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3,4-dihydroxy-n-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine | 4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol | (+-)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol | 46236 | compound 81929 | dl-dobutamine | dobutamin | dobutamina | dobutamine | dobutamine hcl | dobutamine hydrochloride | dobutaminum | dobutrex | doubtamine | posiject | rac-dobutamine | racemic-dobutamine

Organizations (102)

Research & Development (89)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (45)

Approved Indications (2)


 

Cardiac Output, Low

Heart Diseases (approved 1978)

Experimental Indications - Clinical Trial Phases 1-4 (45)


 

Acute Coronary Syndrome (Phase 4)

Acute Lung Injury (Phase 2)

Anesthesia, General (Phase 4)

Angina Pectoris (Phase 4)

Arrhythmias, Cardiac (Early Phase 1)

Asthma (Phase 4)

Brain Injuries, Traumatic (Phase 2)

Cardiac Output, Low (Phase 4)

Cardiomyopathies (Phase 3)

Cardiomyopathy, Dilated (Phase 1/Phase 2)

Cardiomyopathy, Hypertrophic (Phase 4)

Cardio-Renal Syndrome (Phase 3)

Cardiovascular Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 3)

Dobutamine (Early Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 1)

Extracorporeal Membrane Oxygenation (Phase 4)

Fibrosis (Phase 3)

Free Tissue Flaps (Phase 4)

General Surgery (Phase 4)

Head and Neck Neoplasms (Phase 4)

Healthy Volunteers (Phase 4)

Heart Diseases (Phase 1/Phase 2)

Heart Failure (Phase 4)

Heart Transplantation (Phase 2)

Hemodynamics (Phase 2)

Hyperlactatemia (Phase 2)

Hypertrophy, Left Ventricular (Phase 3)

Hypotension (Phase 4)

Infections (Phase 2/Phase 3)

Microcirculation (Phase 4)

Mitral Valve Stenosis (Phase 4)

Mouth Neoplasms (Phase 4)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 3)

Perfusion (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pulmonary Edema (Phase 4)

Renal Insufficiency (Phase 2)

Sepsis (Phase 4)

Shock (Phase 1/Phase 2)

Shock, Cardiogenic (Phase 4)

Shock, Septic (Phase 2/Phase 3)

Tetralogy of Fallot (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 59
  • # of Trial Organizations: 89

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue